Sign inCreate account

Report workspace tools

NCT04707768COMPLETEDanonymous

A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia associated with chronic kidney disease (CKD)

Indication / condition

AI-normalized

Anemia Associated With Chronic Kidney Disease (CKD)

Intervention

Source record

Vadadustat, Mircera®

Source & freshness

Source record

NCT ID

NCT04707768

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2025

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04707768

Title

A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

PHASE3

Condition raw

Anemia Associated With Chronic Kidney Disease (CKD)

Condition normalized

Anemia Associated With Chronic Kidney Disease (CKD)

Modality raw

Anemia Associated With Chronic Kidney Disease (CKD)

Modality normalized

small molecule

Target raw

Anemia associated with chronic kidney disease (CKD)

Target normalized

Anemia associated with chronic kidney disease (CKD)

Interventions

Vadadustat, Mircera®

Public preview

Source record

The trial evaluated the efficacy and safety of vadadustat, an oral treatment, compared to Mircera®, a long-acting erythropoiesis-stimulating agent, for maintaining hemoglobin levels in hemodialysis patients with anemia. The study enrolled 456 participants and was completed in January 2023.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04707768

Status

COMPLETED

Phase

PHASE3

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

The trial evaluated the efficacy and safety of vadadustat, an oral treatment, compared to Mircera®, a long-acting erythropoiesis-stimulating agent, for maintaining hemoglobin levels in hemodialysis patients with anemia. The study enrolled 456 participants and was completed in January 2023.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 15, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04707768

Indication

Anemia Associated With Chronic Kidney Disease (CKD)

Modality

small molecule

Target

Anemia associated with chronic kidney disease (CKD)

Intervention

Vadadustat, Mircera®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.